Akba Conversation (2024)

FAQs

Is AKBA stock a good buy? ›

Akebia Therapeutics's analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts. How can I buy shares of AKBA?

The Wall Street analyst predicted that Akebia Therapeutics's share price could reach $7.50 by Sep 6, 2025. The average Akebia Therapeutics stock price prediction forecasts a potential upside of 455.56% from the current AKBA share price of $1.35.

The average one-year price target for Akebia Therapeutics, Inc. is $5.61. The forecasts range from a low of $4.04 to a high of $7.88. A stock's price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings.

Based on short-term price targets offered by three analysts, the average price target for Akebia Therapeutics comes to $5.50. The forecasts range from a low of $4.00 to a high of $7.50. The average price target represents an increase of 271.62% from the last closing price of $1.48.

What happened. Shares of Akebia Therapeutics (NASDAQ: AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a late-stage study of vadadustat in treating anemia due to chronic kidney disease (CKD) in adult patients not on dialysis.

Largest shareholders include BlackRock Inc., Vanguard Group Inc, Satter Management Co., L.p., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Acadian Asset Management Llc, Renaissance Technologies Llc, State Street Corp, VEXMX - Vanguard Extended Market Index Fund Investor ...

A target price is an estimate of the future price of a stock. Target prices are based on earnings forecasts and assumed valuation multiples. Target prices can be used to evaluate stocks and may be even more useful than an equity analyst's rating.

Fastly Stock Forecast & Predictions: 1Y Price Target $7.81 | Buy or Sell NYSE: FSLY 2024 | WallStreetZen.

Dogelon Mars's price today is $ 0.00000012088839. It might reach $0.000000210 by the end of 2024, but it could drop slightly to $0.000000149. In 2025, we expect the Dogelon Mars price prediction to be worth between $0.000000218 and $0.000000257, which means it might become more valuable.

What is the projection for polygon in 2025? ›

Coincu's Bullish Long-Term Price Prediction for Polygon

One reputed source, Coincu, predicts that Polygon's price may reach an average of $4.61 by 2025, rising to $12.00 by the end of 2030.

Akebia is launching Vafseo® (vadadustat) tablets, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months, which will be available in January 2025 .

According to analysts, AKBA price target is 5.50 USD with a max estimate of 7.50 USD and a min estimate of 4.00 USD.

We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.

Vulcan Materials Company's analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

Vulcan Energy Resources Ltd. has 90.63% upside potential, based on the analysts' average price target. Vulcan Energy Resources Ltd. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

Axos Financial has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings. What is Axos Financial's price target? The average price target for Axos Financial is $82.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.